Bisphosphonates & ONJ Risk
Most offices won’t touch you.
We’ll tell you why — and when we can.
Honest risk numbers for oral bisphosphonates (1 in 10,000), IV oncology doses (1 in 100), and the workflow we use to manage everything in between. UCLA-trained Dr. Henry Qiu, Downey, CA.
- 4.9 Google Rating
- UCLA-Trained
- Lifetime Zirconia Warranty
The Question
The bisphosphonate question deserves an honest answer.
About 1 in 4 women over 65 in the United States is on a bisphosphonate for osteoporosis prevention — Fosamax, Actonel, Boniva, Reclast, or the related drug Prolia (denosumab). Most of them have been told at one point or another that they can’t have dental implants because of the medication. That answer is sometimes right and often wrong, and the difference matters.
The concern is osteonecrosis of the jaw (ONJ): a rare condition in which the jaw bone fails to heal after a surgical procedure and exposes non-vital bone. The biology is genuine — bisphosphonates suppress bone turnover, which is normally how the body remodels and repairs bone after trauma. Suppressed turnover means slower healing. In a small subset of patients, it means no healing at all.
But the absolute numbers matter. For oral bisphosphonates taken for osteoporosis prevention under 4 years, ONJ risk after a dental implant is roughly 1 in 10,000 — meaningful but very small. For IV bisphosphonates at oncology doses (Zometa, Aredia), it’s 1–10%, which is a completely different conversation. Lumping both into “you can’t have implants” is lazy medicine. We do the work to figure out which category you’re in.
When implants are safe
Three categories, three honest answers.
Where you fall depends on the drug, the dose, the duration, and the indication. Here’s the breakdown we use at consultation.
Oral bisphosphonates under 4 years
Fosamax (alendronate), Actonel (risedronate), and Boniva (ibandronate) taken orally for under 4 years carry an ONJ risk of roughly 1 in 10,000. We proceed with PRP and UV-activated implants and have placed in 47 such patients without an ONJ event.
Oral bisphosphonates over 4 years
Same drugs, longer exposure, the math shifts. ONJ risk climbs toward 1 in 1,000. We order a CTX test (a fasting blood draw that measures bone turnover suppression) and discuss a drug holiday with your physician before placing.
IV bisphosphonates / denosumab in oncology
Zometa (zoledronate), Aredia (pamidronate), and Xgeva (denosumab) at oncology doses are a different conversation. ONJ risk is 1–10% depending on duration. We work directly with your oncologist before agreeing to anything elective — and in most active-treatment cases, we don't place implants at all.
The Biology Argument
Why UV-activated titanium and PRP matter even more here.
Healthy bone heals around an implant in 10–12 weeks. Bisphosphonate-affected bone heals slower because the drug suppresses the osteoclast-osteoblast remodeling cycle. The longer the integration window, the more time the implant sits in a partially-healed wound — which is the actual mechanism for the elevated ONJ risk in this patient population.
Two interventions shorten that window. UV photofunctionalization restores the surface hydrophilicity of the titanium implant — a property that collapses while titanium sits on a shelf, and which is the single biggest driver of how fast bone cells adhere to the surface. Twelve minutes under a calibrated UV source resets the surface chemistry to the same hydrophilicity as freshly-manufactured titanium.
Autologous PRP — your own blood, spun and concentrated for platelets — delivers growth factors (PDGF, TGF-β, VEGF) directly to the surgical site. In bisphosphonate-suppressed bone, where endogenous growth factor delivery is impaired, this matters more than it does in healthy bone. Across 47 patients on oral bisphosphonates we’ve placed with this protocol, we’ve had zero ONJ events.
The workflow
Five steps. CTX testing if needed. Honest stop-points if you’re not a candidate.
- 01
Drug history and physician coordination
We need: the exact drug name (oral vs. IV, brand vs. generic), the dose, the start date, and the indication (osteoporosis prevention vs. oncology). We also call your prescribing physician — usually the same day — to discuss the case. About 73% of patients who come in concerned about bisphosphonates are taking an oral medication for osteoporosis prevention, where ONJ risk is genuinely small.
- 02
CTX testing if you've been on the drug 4+ years
Fasting blood draw measuring C-terminal telopeptide — a marker of bone turnover. CTX below 100 pg/mL signals significant suppression and elevated ONJ risk. We won't place implants below 150 pg/mL without a documented drug holiday. The test costs about $90 and we order it from your physician.
- 03
Drug holiday consultation
If CTX is suppressed or you've been on therapy over 4 years, we ask your physician about a 3-month drug holiday before placement. The 2022 AAOMS position paper supports this for most osteoporosis indications. The decision is the physician's, not ours — we provide our risk assessment in writing for them to weigh.
- 04
Surgery with UV-activated titanium + PRP
The two interventions matter even more for osteoporotic bone. UV photofunctionalization restores titanium surface hydrophilicity (which collapses sitting on a shelf), and your autologous PRP delivers growth factors directly to the surgical site. Both meaningfully accelerate integration in slower-healing bone.
- 05
Extended monitoring and conservative loading
Osteoporotic patients integrate slower. We extend the integration window to 16–20 weeks (vs. 10–12 for the standard case) and avoid immediate loading. Follow-up at 2, 4, 8, 12, 16, and 20 weeks. Final monolithic zirconia crown bonded only after we've verified bone-to-implant contact on radiograph.
Our Numbers
What 47 bisphosphonate patients tell us.
0
ONJ events across 47 implants placed in patients on oral bisphosphonates since 2019.
96.1%
5-year survival in osteoporosis patients with UV + PRP protocol. Within 1.7 points of the non-osteoporosis baseline (97.8%).
1 in 12
Bisphosphonate patients we’ve recommended against implants. Honest stop-points matter as much as honest green lights.
Frequently asked
About implants with osteoporosis
- Almost certainly yes, if you've been on it under 4 years. Oral Fosamax for osteoporosis prevention carries an ONJ risk of roughly 1 in 10,000 — meaningful but very small. We proceed with PRP, UV-activated implants, and a 16-week integration window. We've placed in 47 patients on oral bisphosphonates without a single ONJ event.
Take 2 minutes
Bring your medication list. We’ll bring the math.
Two minutes of questions, then Dr. Qiu personally reviews your case within one business day — including coordination with your prescribing physician if needed.
Or call (562) 923-4538
Your Surgeon
The doctor in the room is the one who does everything.
When you book a consult, you're not meeting a sales coordinator. You're meeting me. I'll personally read your CBCT, draft your treatment plan, and quote your exact price — start to finish.
— Dr. Henry Qiu, DDS
UCLA Implant Faculty & Instructor